

targeting immunization of workers born in 1957 or later because they probably do not have natural immunity from prior infection. Nonetheless, screening of healthcare workers born before 1957 for measles immunity still may be warranted because 30% of healthcare workers with reported measles in 1991 were born before 1957.

FROM: Centers for Disease Control and Prevention. Measles Surveillance-United States, 1991. In: CDC Surveillance Summaries. *MMWR* 1992;41 (no. SS-6):1-12.

## Patients with Community-Acquired Hepatitis C Have High Rates of Chronic Hepatitis

Chronic hepatitis was found to develop in a high proportion (62%) of patients with community-acquired hepatitis C. This research finding was reported by Miriam J. Alter, PhD, et al of the CDC's Sentinel Counties Chronic Non-A, Non-B Study Team<sup>1</sup> and provides evidence that the rate of chronic hepatitis following community-acquired hepatitis C is not, as previously believed, significantly lower than the rate following posttransfusion hepatitis C.

Further, severe disease in the form of chronic active hepatitis was more likely to be found in patients who acquired their infection through blood transfusion, suggesting that the size of the infectious inoculum may be associated with the severity of chronic liver disease.

Non-A, non-B hepatitis accounts for approximately 25% of acute viral hepatitis in the United States, and HCV appears to be the etiologic agent of at least 82% of these cases. Parenteral sources of transmission (ie, injection-drug use, transfusion, and occupational exposure) are risk factors for both non-A, non-B hepatitis and HCV infection. Since 1985, however, transfusions account for only 4% of the cases of hepatitis C. Other risk factors identified with HCV infection include household or sexual contact with an infected person and multiple sexual partners. In addition, low socioeconomic level is associated with a large proportion (an average of 30%) of cases of both non-A, non-B hepatitis and hepatitis C. This risk factor is probably a surrogate marker for other routes of transmission and makes prevention of disease difficult because of its nonspecific nature.

The uniformly high rate of chronic hepatitis found in patients after HCV infection suggests that HCV may be a major cause of chronic liver disease in the United States. In most patients, HCV infection seems to persist for at least several years, even in the absence of active liver disease, emphasizing the urgent need for development of preventive strategies for those in risk groups unassociated with blood transfusions.

## REFERENCE

1. Alter MJ, Margolis HS, Krawczynski K, et. al. The natural history of community-acquired hepatitis C in the United States. *N Engl J*


## New Procedure Allows Detection of HIV in Blood of Nearly All Infected Persons

A new procedure developed by researchers at the University of California, San Francisco (UCSF), appears optimal for detecting HIV in the blood on infected individuals. In the past, free human immunodeficiency virus (HIV) could be found in the plasma of only about 35% of infected people, reported Dr. Li-Zhen Pan et al at UCSE Effective detection of the virus depends on using an enzyme-linked immunosorbent assay (ELISA) for p24 core antigen of HIV and adding the HIV-infected plasma to target cells.

This testing procedure has confirmed that free virus can be detected in the plasma of almost all individuals infected with HIV if the blood is analyzed within three hours after it is drawn. The researchers confirmed the previous work of other researchers that levels of virus reflect patients' clinical status, with healthier people having less virus and those with very high CD4 + cell counts having less but still detectable virus.

The three-hour window is important for accurate results because beyond this time period substances in the blood such as neutralizing antibodies begin to inactivate the virus so that it is undetectable. However, if plasma and serum samples are frozen and stored at  $-70^{\circ}\text{C}$ , the virus will remain detectable for up to several months. The researchers noted that this procedure is not suitable for initial HIV screening because it is a lengthy procedure. FROM: Pan L, Werner A, Levy JA. Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. *J Clin Microbiol.* 1993;31:283-288.

# KNOW THE LITERATURE



**The U.S. Department of Education has published a booklet entitled Growing Up Drug Free—A Parent's Guide to Prevention. Within its pages, you will find valuable advice on how parents can keep their children drug free, as well as specific things to watch for if they suspect drug abuse.**

PLEASE SEND FOR A SUPPLY OF FREE COPIES FOR YOUR PATIENTS

Call the Department of Education's toll free number: 1-800-624-0100  
In Washington, DC: 202-785-1161

or *send your name and address to:*

Growing Up Drug Free  
Pueblo, CO 81009

or

National Clearing House for Alcohol and Drug Information  
P.O. Box 2345, Rockville, MD 20852

## PARTNERSHIP FOR A DRUG-FREE AMERICA

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. Copyright and Republication Policy

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. hold copyright on *Infection Control and Hospital Epidemiology*. We request that all authors of works transfer to SHEA and SLACK Inc. all rights, title, and interest to such works, including copyright. In accord with the Copyright Act of 1976, we must acquire every author's signature to effect the transfer. A written work cannot be considered for publication until the "Assignment of Copyright" form is signed by the author or authors and is on file at the editorial offices. Please submit this signed form with your manuscript. In the event that a manuscript is not accepted for publication, this agreement will be returned to the authors.

Signed "Assignment of Copyright" forms confirm that a work submitted has not previously been published, is not subject to copyright or other rights except those of the author to be transferred to SHEA and SLACK Inc., and is not under consideration for publication elsewhere, except under circumstances communicated in writing at the time the work is submitted.

Permission to reproduce any part of the works published by SHEA and SLACK Inc. in *Infection Control and Hospital Epidemiology* in any form or by any means, electronic or mechanical, is not permitted without written permission from SLACK Inc.

### Assignment of Copyright

In consideration of SLACK Incorporated and The Society for Hospital Epidemiology of America (collectively called the "Publisher") in publishing my (our) submitted manuscript, the undersigned hereby transfer(s), assign(s), and otherwise convey(s) all copyright in the manuscript to the Publisher. The undersigned declares that the manuscript is original and, to the best of the undersigned's knowledge, contains no matter that is libelous or unlawful or that infringes upon anyone else's rights of copyright.

In addition, we affirm that the work is the work of every author listed and is not under consideration for publication elsewhere, except under circumstances communicated to the Publisher in writing at the time the work is submitted.

MANUSCRIPT NUMBER (if known) \_\_\_\_\_ DATE \_\_\_\_\_

AUTHORS \_\_\_\_\_

TITLE \_\_\_\_\_

### ALL AUTHORS

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

\_\_\_\_\_ This form may be photocopied. \_\_\_\_\_

# KEEP UP WITH NEW JCAHO REQUIREMENTS BY USING AICE®

The AICE® Software System is continuously being enhanced to keep you abreast of changing Joint Commission demands.

“Compliance” and “easy” are not words normally heard in the same sentence--not until the **AICE Software System** was developed to meet the complex demands of infection control. **AICE** enables compliance with the epidemiologic and statistical standards using an easy step-by-step model. Use **AICE** to:

- ◆ Calculate specific infection rates (by surgeon, service, unit, etc.)
- ◆ Provide 3-way rate tables stratified by risk
- ◆ Easily feedback these rates to the employees/physicians who can make a difference
- ◆ Send follow-up lists and letters to physicians
- ◆ Conduct priority-directed/targeted, problem-oriented, and/or total house surveillance
- ◆ Identify clusters of infections on incidence graphs
- ◆ Track thresholds on graphic reports
- ◆ Perform case-control and special studies
- ◆ Compare hospital infections in-house with data trend analyses
- ◆ Watch the decline of infection rates and patient morbidity!

Today's hospital information management systems require ways to transfer data back and forth between computers. Do you want to download data from the operating room computer into **AICE**? Do you want to upload **AICE** data into other hospital databases or even into the Joint Commission's beta test software? **AICE** has solutions for you.


**AICE** is designed for both the novice and experienced computer user. With our 6 months of toll-free support, we will have you up and running on **AICE** in no time!

It is time to deal yourself a winning hand.



**Order AICE Today!**  
**For more information write or call**

**(800) 426-8015**



**Infection Control and  
Prevention Analysts, Inc.**  
4425 South MoPac Expressway  
Suite 205  
Austin, TX 78735

See us at APIC Booth #118

*Ask about Respond! EHMS®  
our software for Employee Health.*



# Membership Application

The Society for Hospital Epidemiology of America

Name \_\_\_\_\_

Degree  MD  PhD  Other \_\_\_\_\_

Title (in hospital epidemiology) \_\_\_\_\_

Institution(s) name and address \_\_\_\_\_

City State Zip code

Business telephone (\_\_\_\_\_) \_\_\_\_\_ Fax (\_\_\_\_\_) \_\_\_\_\_

Area of interest within hospital epidemiology

- Hospital-acquired pneumonia
- Intravascular device-associated infection
- Nosocomial urinary tract infection
- Other (specify) \_\_\_\_\_

Bed size \_\_\_\_\_ Category  Non-Teaching  Teaching

Home address \_\_\_\_\_

City State Zip code

Home telephone (\_\_\_\_\_) \_\_\_\_\_

Indicate preferred address for membership directory  Home  Business

## Membership fees

Non-US members please pay with draft for US dollars.

**CI Active membership**—Calendar year dues: \$85

**Applicants must hold** a doctoral degree and should either work in the field of hospital epidemiology or have a **direct interest in hospital epidemiology.**

**Associate** membership—Calendar year dues: \$35 Fellowship ends (month)\_\_\_\_\_/ (year)\_\_\_\_\_

**Applicants must hold** a doctoral degree and be participating in an appropriate training program in the field of **hospital epidemiology. Proof of training must accompany this application.**

Your membership fee includes a subscription to the Society's official journal  
*Infection Control and Hospital Epidemiology.*

Please make checks payable to The Society for Hospital Epidemiology of America.

### Send application and remittance to:

SHEA Membership  
875 Kings Highway, Suite 200  
West Deptford, NJ 08096  
(609) 845-7220  
(609) 853-0411 FAX



# We've made it easier to spot the benefits of infection protection.

By now, nearly every physician knows the benefits of central vessel catheterization. But you also know the infection risks. Catheter-related infections are estimated to occur in 3% to 12% of central vessel catheterizations,<sup>1</sup> and 20% of those are fatal.

Until now, all you could do was look for ways to treat the problem. But today you can look for a way to prevent it. ARROWgard™ Blue.<sup>2</sup>


Catheters with the ARROWgard™ Blue antiseptic surface are up to 80% less likely to develop bacteremia than unprotected catheters! The benefit to the patient is immense.

ARROWgard™ Blue is also worth looking into for financial reasons. Each CVC infection costs about \$8,000 to treat, so a 3% infection rate would cost a hospital placing 1,000 CVC's about \$180,000 per year.<sup>4</sup> If

ARROWgard™ Blue cuts that rate in half, a hospital would save \$90,000. Given today's focus on medical costs, catheters with ARROWgard™ Blue offer the unique benefit of saving more than they cost.

Plus, ARROWgard™ Blue is built into the catheter. So you don't have to dip it or slip it on. You just have to look for the blue.

To learn more about the benefits of ARROWgard™ Blue, contact your Arrow International, Inc. representative, or call 1800 538-2317 and ask for Joanne.



ARROWgard™ Blue. *Now you can see infection protection.*



# ARROW®

1 Elliot, TSJ: Intravascular-device related infections. *J. Med. Microbiol.*; 27:161-167; 1988.

2 ARROWgard™ is a joint development of Dallex Medical Services, Inc., and Arrow International, Inc., using technology developed by Dr. Shanta Modak and her colleagues, in the Department of Surgery, Columbia University. U.S. Patent Numbers 4,612,337, 4,563,485, 4,581,028, 5,019,096 apply. Other U.S. and foreign patents pending.

3 Maki, DG; Wheeler, SJ; Stoltz, SM: Study of a novel antiseptic coated central venous catheter. Presented at the Society of Critical Care Medicine Annual Symposium; Washington, D.C., May 1991.

4 Hampton, AD; Sheretz, RJ: Vascular-access infections in hospitalized patients. *Surg. Clin. North Am.*; 68:57-71; February, 1988.

Refer to package insert for current warnings, precautions, and instructions for use.